

argenx

2021 Environmental, Social and Governance Report

Table of Contents

On the Cover

Eri is a dedicated father, friend, railroad inspector, athlete, and so much more. He is also living with generalized myasthenia gravis. Peter is a stellar scientist and the head of our clinical science at argenx. Professor Sally Ward is our scientific collaborator and a pioneer of FcRn biology. Dr. James Howard is a practicing neurologist who treats people living with gMG and primary investigator on our Phase 3 ADAPT trial. Gina Meza Hultz is a passionate nurse and argenx Nurse Case Manager who supports connection to care through our patient support program. Together, where breakthrough science meets significant unmet need, we're working to redefine immunology.

Tim Van Hauwermeiren
CEO & Co-Founder

Message from our CEO

"The future belongs to those who dare to do more."

Our goal at argenx is to improve the lives of people suffering from severe rare diseases. In order to achieve this, we know we need to build an independent, fully-integrated and sustainable immunology organization.

The name "argenx" was inspired by the story of the Argonauts, the first story on record to recognize the power of the team rather than individual heroes. The Argonauts set out in a small boat on a wide ocean to bring back the golden fleece, a seemingly impossible task. Alone each of these individuals could not have succeeded, but banded together they achieved the unthinkable. By joining argenx, we are all choosing to join the adventure, to be part of this team looking to achieve something truly great.

Greatness to us means going above and beyond for all our stakeholders. It means delivering innovative therapies that improve the lives of patients and their families; fostering a culture of excellence and empowerment for our people; co-creating new immunology breakthroughs alongside our innovation partners; and supporting long-term value creation for our shareholders.

This sentiment extends beyond the reach of the argenx innovation ecosystem. We recognize and fully embrace our part in creating a better future not just for the patients and communities we hope to serve, but the global community around us. We live this purpose every day, and in 2021 took concrete steps to formalize and document both our commitment to corporate citizenship and the actions we have taken in our environmental, social and governance (ESG) initiatives. This inaugural ESG report embodies our commitment to leave the world a better place than we found it and to have a real and lasting impact on our communities, patients and people.

We know that this is just the beginning. There will always be more work to do on this topic, and we look forward to bringing our stakeholders along with us every step of the way. As one team, with one purpose, we hope to foster a culture of collaboration, sustainability, and integrity as we strive to transform the lives of patients and communities around the world the right way – the argenx way.

All metrics as of December 31, 2021.

The argenx Purpose

argenx emerged from a breakthrough antibody engineering innovation and a philosophy that collaboration is key to success. From these origins, we have built a reputation of consistent execution, hard work and integrity on our path to deliver immunology breakthroughs to the patients who need them.

Our purpose is immunology innovation. Through our Immunology Innovation Program (IIP), we have built a differentiated pipeline of antibody candidates with the goal to deliver new options to people who are living with severe and rare autoimmune diseases worldwide.

We are the leader in neonatal Fc receptor (FcRn) biology. Thanks to our longstanding collaboration with Professor Sally Ward and her research team at UT Southwestern who uncovered the role of FcRn in IgG homeostasis.

- VYVGART® is the first and only approved FcRn blocker in the U.S. (efgartigimod alfa-fcab) and Japan (efgartigimod alfa) for the treatment of generalized myasthenia gravis (gMG)



800+
Employees globally

2
Compounds in pre-clinical development

6
Compounds in clinical development

12
IIP discovery programs ongoing

19
Active clinical trials

1300+
Clinical trial patients treated with our pipeline candidates

$581M
Invested in R&D in 2021

6
Pipeline candidates out-licensed to partners

- We are evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within our therapeutic franchises. In addition to gMG, efgartigimod is also in development for: primary immune thrombocytopenia (ITP), pemphigus, chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic inflammatory myopathies (myositis) and bullous pemphigoid

- Efgartigimod is expected to be under evaluation or approved in 15 indications by 2025

Our Philosophy on ESG

At argenx, our commitment to ESG is not just about satisfying a requirement.

It is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company. Our mission sits at the intersection of critical patient need and breakthrough science. We aim to operate in a way that impacts the key stakeholders of this mission: patients and their supporters, our employees, our research collaborators, and the broader community. We use the Sustainability Accounting Standards Board (SASB) standards as a framework of reference to report our metrics and initiatives. Instead of adhering strictly to, and reporting only metrics within a specified reporting framework for ESG, we have opted to focus our reporting on the key metrics and initiatives that best illustrate our company DNA and how we bring our core values to life. At the end of the report, we have included reference tables to help find certain metrics throughout this report, including the metrics compatible with the SASB framework.

Innovation

Our Core Mission

We live to innovate- and do so at every step

Co-Creation

We Create Through Collaboration

We trust in the power of the team and know that together we are better

Empowerment

We Share in Our Joint Purpose

Our people are our most valuable asset

Excellence

We Have a Quality Culture

We want to do things right the first time and prioritize patient safety

Humility

The Heart of Our Organization

We want to handle successes and challenges gracefully and learn from both

Innovation

Innovation is our core mission – it is our *raison d'être.*

We live to innovate and do so at every step:
- o building new molecules
- o designing clinical trials
- o engaging with patients and physicians.

We know that Innovation can happen when you least expect it- from the unexpected finding or encounter. It happens at the interface of different disciplines and when we bring together diverse backgrounds and opinions. Some of our best ideas originate from interactions with people around us – both with each other and outside the argenx walls with our external partners. We aim to create space to allow us to generate new and diverse experiences, and to continue to be externally facing where practical. This allows us more opportunity to encounter innovation. For more information on this please visit www.argenx.com/innovation.

The value we can bring to patients with our medicines starts with our continued ability to innovate.

We focus our pipeline on programs that address rare disease and orphan indications argenx engineers first-in-class therapies for rare autoimmune diseases – where underserved patients need breakthrough therapies and the healthcare community needs options.

Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering on others.



Our Medicines

At the date of this ESG report, we have one approved product (VYVGART®) in our portfolio. We are also developing efgartigimod in additional indications. We have two additional product candidates in our clinical stage development pipeline. In addition, we have six product candidates in clinical development in partnership with third parties. We have three preclinical product candidates under development.

- Our lead asset, VYVGART® is approved in the United States for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, and in Japan for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). VYVGART® is the world's first-and-only approved neonatal Fc receptor (FcRn) blocker.
- Generalized myasthenia gravis is a rare and chronic neuromuscular disease characterized by debilitating and potentially life-threatening muscle weakness. VYVGART® is a human IgG1 antibody fragment that binds to FcRn, resulting in the reduction of circulating immunoglobulin G (IgG) antibodies. The action of AChR autoantibodies at the neuromuscular junction is a key driver of gMG[1].

[1] *Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicenter study. Lancet Neurol. 2017; 16: 976-86*

Access to our Medicines

argenx is committed to supporting affordable access to VYVGART®

- As part of this commitment, we launched My VYVGART® Path, a program designed to connect patients and clinicians to personalized support throughout the VYVGART® treatment journey.
- My VYVGART® Path focuses on personalized support to prioritize the needs of patients. Our team of Nurse Case Managers offers specialized attention to patients, and supports them with benefits verification and reimbursement, disease education and resources to assist with co-pay and other costs associated with accessing VYVGART®.
- Through My VYVGART® Path, healthcare providers can also receive assistance from a dedicated case coordinator for insurance needs from the provider perspective
- argenx has a Pre-approval Access (PAA) Program to provide access to our investigational medicines outside of a clinical trial setting for patients who have exhausted all available treatment options and are not eligible for clinical trials. We have PAA programs open in the U.S., Canada, and Europe. For more information, please access argenx.com/information-on-pre-approval-access.

Co-creation

We create through collaboration, bringing two or more parties together to create something more powerful than each could achieve individually. We know that together we are better. We know where our strengths lie, individually and as a team. We also know where we should rely on the knowledge of others. We are a learning organization, constantly seeking input and new perspectives from our partners in co-creation.

There are many examples of co-creation across our project-based organization, including how we interact with patient communities and how we collaborate with leading disease biologists through our Immunology Innovation Program. We want to access the expertise and knowledge we believe best serves our mission. This means that in addition to our commitment to hiring the best talent, we also collaborate with outside consultants.

Through co-creation, we unite the patient and the science on our mission to seek out breakthroughs in innovation. We believe that when you follow scientific breakthroughs to meet the needs of patients, the opportunity is limitless.

Where **critical patient need** meets
breakthrough science,
That is where we **redefine immunology**



Our mission is **innovation**

To the patients we aim to serve: we see you, we hear you, we are here with you.

Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We are pioneering innovations to advance the understanding of rare diseases; our vision is to deliver innovative immunology treatments to patients worldwide.

We listen to patients, supporters and advocacy communities, and integrate their aspirations into how we innovate, how we conduct research and design trials, and how we can help alleviate the daily struggles they face living with a rare disease.

Linda

“ It is very important to me and others like me that new innovations are developed in clinics so that we can continue to have hope for better treatments and an improved quality of life.”

Kelly

“ All I have ever wanted is to help provide a voice for those who do not have one and to offer support to patients like me. I am so fortunate to have found myself at the GBS|CIDP Foundation in a role that does just that.”

David

“ Pemphigus vulgaris has changed the way I live my life. I'm always watching for new blisters and lesions and questioning anytime I feel something strange.”

Engaging the Patient Community



A Mystery to Me Documentary

A Mystery to Me, produced by award-winning Sarofsky Productions, is the first-ever docuseries dedicated to the MG patient experience. The film shorts illustrate the perseverance of three individuals navigating the challenges of living with this debilitating disease.

18,162

Views – as of December 31, 2021

MG United

MG United is a lifestyle platform dedicated to the MG community that provides personalized, carefully selected resources aimed at addressing the unique ways MG can affect their lives. These include but are not limited to educational articles, real and relatable stories of struggle and success, caregiver guides, and exclusive access to A Mystery to Me and Cooking Together, an MG-friendly cookbook.

40,000+

Opt-Ins – as of December 31, 2021

1,738,767

MG United website visits as of December 31, 2021

MyRealWorldMG

argenx partnered with patient organizations from 10 countries to launch MyRealWorldMG™ (MRW-MG), an international real-world evidence study assessing the impact of myasthenia gravis on patients' lives. There are currently 1,760 global MG patients enrolled in the app-based study, inputting data on their experience with this debilitating disease.

1,760

Global MG patients enrolled

Advocacy

- **18** live and virtual patient events in 2021
- **Advocacy Leadership Council:** Our Global Patient Advocacy team fosters strong relationships with patient advocacy organizations around the world. To build a two-way street of insight gathering and resource-sharing, we convened an Advocacy Leadership Council of 12 patient advocacy organization leaders who meet quarterly
- **We Hear You Project:** In 2021, we launched a digital initiative to collect input from the ITP, CIDP, and PV patient communities. Similar to our approach to connecting with the MG community, we know we can only address the burden of these diseases if we understand patients' aspirations and the daily struggles they face.

2,000+

MG community engagements 2021

"We listen to and learn from people with rare diseases so that we can better address the real-life challenges they face.

The strength and resilience of the MG community humbles us every day, and we felt compelled to tell the stories of these remarkable individuals to a broader audience."

– Tim Van Hauwermeiren
Chief Executive Officer on the A Mystery to Me documentary

Our Commitment to Science

We are on a mission to build the next great integrated immunology company by bringing breakthrough therapies to patients around the world. We cannot achieve this alone and rely on our scientific partners in co-creation as we build out our pipeline with differentiated antibody candidates.

Immunology Innovation Program

- The Immunology Innovation Program (IIP) is our discovery engine. It is an innovation ecosystem that unites our unparalleled antibody engineering expertise with top notch disease biology experts around the world.
- The goal of the IIP is simple: connect our expertise with that of our collaborators to deliver potential new therapeutic options as quickly as possible to the patients who are waiting.
- Each of our pipeline candidates that have been developed since our founding has a story of co-creation behind it. We collaborate with leading disease biologists, applying our powerful antibody engineering technologies to a potential first-in-class therapeutic opportunity. Together we can unravel new disease pathways or targets.
- To support the continued advancement of our pipeline, we hired over 100 people on our Research & Development teams in 2021.



Stepping into these strategic, academic, industry collaborations. This is a wonderful ecosystem that we are creating, by bringing that expertise together.

– Bart Lambrecht, M.D., Ph.D,
Professor, VIB, argenx Collaborator

Case Study of Immunology Innovation Program

ARGX-117 is our wholly-owned complement inhibitor targeting C2. It was built in collaboration with Professor Erik Hack, Ph.D. from UMC Utrecht. Professor Hack is known for his renowned research in the role of inflammation in disease, specifically in the complement system, and has contributed research and expertise to the approval of two complement inhibitors.

His deep understanding of the complement cascade guided us as we optimized ARGX-117, designed first-in-human trials, and identified initial indications into which to advance the program.

"It's nice to work with argenx because they are truly science-driven. I have not always had this type of experience with other companies. We arrived at a good inhibitor molecule because we made data-driven decisions rooted in strong biology and I appreciate this process and collaboration greatly."

– Erik Hack, Ph.D.
Retired Professor of Immunology,
UMC Utrecht

ESG Report 2021

We are argenx

Empowerment

One team, one purpose. We are argenx.

Our global team of Argonauts is the compass that steers us in the right direction and acts as the oars that drive us ahead on our mission. Our culture stems from the collective power of the team and the understanding that together, we are better.

We build on each other's strengths and align the growth of our employees with the shared goals of the organization. Together we are one team, with one culture, and one purpose – to improve the lives of patients living with severe autoimmune diseases.

In 2021, our team more than doubled, with now 854 Argonauts employed around the world, 678 of whom are full-time employees.

- As at December 31, 2021, our Board of Directors consisted of 8 directors, including 1 executive director and 7 non-executive directors. The full board contained 6 male directors (including 1 executive director) and 2 female directors (non-executive), translating into a 75% male / 25% female balance for our full board of directors and a 71.4% male / 28.6% female balance for our non-executive directors.
- As at December 31, 2021, our company leadership team consisted of 23 persons of whom 14 male (60%) and 9 female (40%) persons. For the purpose of this statement we defined the leadership team as consisting of our C-level people as well as the leaders of our largest functions and projects. Each of these positions is characterized by high-impact across the organization, leading a global and cross-functional team and having a global reach.
- As at December 31, 2021, 58% of the members of our workforce who disclosed their gender identity, were female, and 42% male.

As of February 1, 2021, within our full-time team:

58%
of total workforce is female

10%
of employees are under 30 years old

64%
are 30-50 years old

26%
are over 50 years old

71.4%
of our non-excecutive directors are male (5)

28.6%
are female (2)

Diversity Policy

Why diversity, equity and inclusion matters

We value diversity among our colleagues as an integral component in building a sustainable growth platform. We believe that a diverse workforce enhances our overall performance and success. We take pride in creating and sustaining a culture and environment where each of us can excel. We bring together people with diverse backgrounds, experiences and functional expertise. By doing so, we broaden the scope of ideas and creativity essential to developing and delivering innovative therapies to patients. Acknowledging and benefiting from different perspectives promotes diversity of thought and empowers innovation. It also contributes to our commitment to improve lives of patients, wherefore we need teams with a healthy mix of contrasting perspectives and backgrounds that reflect the diverse communities we serve.

We recognize that our people are our greatest strength. Fostering an inclusive work environment where everyone feels safe and encouraged to contribute leads to better work outcomes and supports high levels of employee commitment and retention. We aspire to be a consciously global company. Our success is built on, and dependent on true collaboration in cross-functional and often cross-regional teams in which open communication is encouraged and safeguarded. Everyone has a voice and is encouraged to contribute to the benefit of our common goals, irrespective of race, ethnicity, age, gender or cultural background. Good ideas as well as real concerns are taken seriously, regardless of who brings them forward.

Our approach to diversity, equity and inclusion

Our commitment to diversity, equity and inclusion is embedded in the way we recruit, develop and promote our employees. We value our fair, inclusive recruitment process, which is standardized across the organization and focuses on pre-identified 'what counts' factors. The process involves a diverse group of colleagues from across the organization, who are provided with training to recognize any existing biases. Recruitment decisions are based on a group evaluation of available candidates, effectively capturing different perspectives. Our onboarding program is designed to promote inclusion by building social fabric across teams, functions and geographic locations. Furthermore, all employees are encouraged to participate in a personal development program aimed at building on their individuals strengths to benefit the broader team. We offer opportunities for promotion, training and career development solely based on job-related, appropriate criteria such as skills, competencies, experience, aptitude and enthusiasm and giving account to each individual's ambitions and capabilities.

Our goals

We aim to foster an inclusive work environment in support of our strategic plan and priorities. We continue to raise the bar in this regard, and to commit to measures and goals designed to support our maturing company culture. We aim to have an equal gender balance in our board of directors and in our company leadership (including functional leaders and project leaders). For the medicines we develop we strive to ensure that participants in our clinical trials adequately represent the patients who will ultimately use them.

Our values

Our diverse, equitable and inclusive work environment is reinforced by our established values, which guide our business relationships and collaborations both within and beyond our walls: Co-Creation, Humility, Excellence, Empowerment, Innovation. To further support and encourage our employees to 'live our values', all our employees set annual individual performance targets specifically aimed at building our organization in line with our core values. Furthermore, we welcome global and local initiatives to encourage diversity, equity and inclusion.

People Development

By joining argenx, we are all choosing to join the adventure, to be part of this team looking to build the next great integrated, immunology company that is rooted in science, data-based in our decision making and always focused on the patient.

Personal Development Plans

- We aim to lift each other to our highest performance and have created a learning and development experience to achieve this through our Personal Development Plan (PDP). With the PDP, we aim to identify and maximize a person's strengths.
- We can also find the place within the business for this individual to make the greatest impact. By aligning the interests of the individual with the interest of the business, we can optimize the energy and enthusiasm of our organization.

INSIGHTS Program: Developing Future Leaders

Each year, a group of high-potential leaders are selected for the INSIGHTS program. The program has the following objectives for its participants:

- Build broader understanding of the overall argenx business plan through interaction with executives
- Facilitate team-building across the organization working together as a team
- Gain deeper insights into self-awareness and self-management
- Build leadership skills based on framework of Envisioning-Engaging-Energizing-Enabling-Executing
- Serve as a mentor by transferring key learnings to other colleagues who are earlier in their careers

Hiring and Retention

Our future success is largely dependent on our ability to attract and retain highly qualified employees, and to motivate and incentivize them to contribute to our long-term success. Our talent recruitment, development and retention schemes are applied throughout our organization, across regions and functional areas.

Our short-term incentives include:

- Annual variable pay is paid upon achievement of individual pre-defined goals, which align with our corporate objectives, specifically around:
  - Building the Business: Setting targets aimed at achieving our strategic business objectives
  - Building the Organization: Setting targets aimed at building and improving our organization in line with our cultural pillars
- A corporate bonus consisting of a fixed amount equal for all that is tied to company-wide goals; for 2021, the corporate bonus targets related to:
  - Empowerment: 'No Strangers' objective to drive successful cross-functional, cross-regional engagement among Argonauts
    - o Each Argonaut accepted the challenge to connect directly with at least five new colleagues throughout the year and to record their learnings or observations from the experience
  - Co-creation: One-company, one-culture buddy system with the challenge to form a minimum number of 'newcomer-buddy' pairs
  - Excellence: Successful FDA inspections and PMDA inspections in relation to the marketing approvals of VYVGART® in the U.S. and Japan
  - Humility: 100% training target for our new Code of Business Conduct and Ethics

Our long-term incentives consist of:

- The grant of stock options and restricted stock units under our equity incentive plan, in which all argenx employees and directors are offered the opportunity to participate

Our equity incentive plan serves to:

- Position all employees as co-owners of our business, allowing them to share in the sustainable future success of argenx
- Incentivize employees to favor long-term value creation over short-term success
- Reward employees based on their contributions to our mission by making new grants subject to their continued high performance
- Promote retention by making the vesting of incentive grants subject to long-term commitment to, and involvement with argenx

Employee Engagement

Communications and Social Media Councils

- The argenx Communications and Social Media Councils are made up of a unique group of Argonauts spanning teams, management levels, and geographies. The councils review company-wide internal communication and social media programs and collect input from participants with the aim of ensuring these communications reflect our "one company, one purpose" corporate culture.

Buddy Program

We operate a buddy system to help newcomers navigate our organization with the goal of accelerating their integration and learning during their first months at argenx. We offer newcomers the opportunity to be coupled with a person of trust to help them navigate any challenges as they onboard. The Buddy Program additionally serves to stimulate networking outside of the newcomers' own functional team, exposing them to other parts of the organization and encouraging cross-functional collaboration immediately. The integration of newcomers into the organization is a shared responsibility of everyone – we want to be a team of argenx Ambassadors.

The Buddy Program was launched in 2021 and is viewed company-wide as a successful initiative, with 150+ duos formed as of December 31, 2021.

Employee Engagement Workshops

Initiated by members of the INSIGHTS team, we held two half-day workshops in 2021 that were facilitated by external consultants specialized in the field of employee engagement. The outcome of the workshop focused on four key topics to further employee engagement as we continue to grow:

- Build agile processes around decision-making to empower employees
- Bring cultural pillars to life to guide us in achieving our goals
- Broadly communicate priorities within our strategic plan so that every employee aligns with the WHY
- Leadership development at all levels

Excellence

We live by our reputation for making data-based decisions- not based on hierarchy, tenure or by speaking the loudest but by trusting the quality of our data. We want to do things right the first time by integrating quality from the start of all business processes and seeking out efficiencies through continuous improvement.

Quality

"Quality is at the heart of everything we do."

– Andria Wilk, Global Head of Quality

To achieve our goal of delivering innovative therapies to patients, a quality-focused mindset must be exercised at every step of our execution from the preclinical stage to the commercial stage. The Argonauts that make up our Quality team work diligently to ensure this applies across all segments of the business. We also have Quality representatives within each of the functions who work together with the Quality team to ensure we do things right the first time and to the highest quality standard.

To ensure quality in how we run clinical trials, we take the following measures:

- Good Clinical Practice (or GCP) manager assigned to all studies to proactively identify and address potential areas of non-compliance.
- Clinical Operations Quality lead who oversees operational quality across all studies and works in close concert with the GCP managers.
- Standard operating procedures (SOPs) that are accessible, user-friendly and facilitate compliance.
- Vendor assessment procedures to ensure they are capable of and continually delivering on providing quality trials.
- Effective training, real-time sponsor oversight, and risk-based audits conducted at the start, during and conclusion of studies so we can continuously improve and be inspection ready from day one.

Global patient safety in pharmacovigilance is a top priority of our quality commitment:

- We put patients first and take into account the needs of caregivers, healthcare providers, and other relevant stakeholders and strive to be proactive, risk-based, and continuously adaptive to provide transparent communication and ensure cooperation between all stakeholders.
- Ensuring quality by design regarding our global patient safety efforts is a scientific and strategic driver for the company and allows us to comply with legal requirements, prevent harm, promote safe and effective use, and most importantly, protect patient and public health.

We uphold our colleagues to high quality standards in our vendor selection strategy:

- Including a quality evaluation step for all vendor selections through vendor quality assessment questionnaires and qualification audits
- Data-driven Request for Proposal (RFP) selection process, effective contract management and budget negotiation, and continuous operational and quality oversight.

To ensure high quality product is supplied to patients:

- A team of GMP quality professionals is overseeing development and commercial programs
- Management of suppliers is key, including maintaining robust partnerships with clear agreements in place governing quality and technical aspects and routines
- Issue and risk management practices are embedded in the argenx Quality Management System
- Compliance to internal standards and regulations is of primary importance to secure argenx's licence to operate

Product Traceability and Preventing Counterfeiting

As managing global supply chains becomes increasingly complex, argenx is committed to implementing solutions to manage product traceability and to prevent counterfeiting.

To the extent this is required by national legislation (e.g. DSCSA in US and FMD in EU), all commercial argenx products are serialized at unit, case and pallet (aggregated level). On each sellable unit a unique random serial number is printed, as well as a product code, lot number and expiry date, both in human readable format and encoded in a 2D data matrix barcode. A dedicated software database is used to generate and maintain the status of the serial numbers and interface with the relevant partners in the supply chain. All products are tamper evident sealed during manufacture and shipper systems and trucks are tagged with numbered seals in transit to prevent product tampering.

During batch manufacturing (outsourced to contract manufacturing organizations, or, CMOs), all processing steps are documented to have a full processing history and lot genealogy of consumed raw materials, which is also maintained in the CMOs' quality system. An ERP system is used to provide full lot genealogy and traceability of intermediates and finished products owned by the entity (argenx), located at its CMOs, third party warehouses and 3PL distributors, or in transit. For downstream distribution, the entity can rely on the distributors' and wholesalers' systems to trace product to the end customer at lot level.

We have a procedure in place to ensure that all suspicions of falsified or counterfeit medicine are reported in a consistent manner. When a case is reported, the impacted batches will be segregated and quarantined, an investigation will be performed and the impacted stakeholders in the supply chain will be informed, as well as the relevant competent authorities in case of confirmed counterfeit product. Market actions will be taken in consultation with the competent authority.

Environment

argenx is dedicated to conducting its business in a safe and environmentally sustainable manner as part of our commitment to not only improve the lives of patients we hope to serve, but also to positively impact our colleagues, business partners, and surrounding communities.

To achieve this we:

- Comply with environmental laws and regulations that are related to our specific work and responsibilities
- Encourage colleagues to respect the environment and natural resources available to us by taking sustainability steps like limiting energy use, reducing waste, and recycling
- Have awareness and training programs to teach our employees how to use different waste systems

We are committed to expanding and developing our sustainability initiatives in the future.

In Belgium, there is a strict regulation concerning waste management. We collect our waste streams in different fractions and every fraction is treated as required. Our waste streams from the labs are separately collected and handled by a waste processor.

- In our Zwijnaarde, Belgium location, waste fractions are treated as such:
  - Paper and Cardboard, Hard Plastic, Transparent Foil, Colored Foil, Glass, Polystyrene, PMD (Plastics, Metal cans, Brick packaging of beverages):
    - o 100% recycled
  - Liquid Waste (Non-flammable, water-based):
    - o Physicochemical treatment and detoxification at waste processor location
  - Biological Waste:
    - o Collected separately and incinerated with energy recuperation
  - Electronic Waste:
    - o 100% recycled by specialized waste processor
    - o If applicable, cooling agents are recovered during this recycling process (e.g. the recycling of fridges, freezers, incubators etc.)
  - Remaining Waste (Domestic type of waste from cafeteria etc.):
    - o Sorted by waste processor in compostable and recyclable fractions
    - o A very limited part of this waste stream is incinerated with energy recuperation

Our Belgium office also complies to the Energy Performance regulation in Belgium. We are currently working on programs to assist employees that prioritize more energy efficient modes of transportation such as bicycling or public transportation.

We do not have an environmental policy. We conduct our activities within the environmental regulatory framework set out by those jurisdictions we operate in and have obtained all required environmental licenses and permits. With the goal to mitigate the risk of failure to obtain any required environmental permits or licenses, or of losing granted permits or licenses we may need to operate our business, we regularly evaluate the requirements of such environmental permits and licenses to ensure continued compliance.

Humility

Humility is the heart of our organization. This cultural value has been key to our operations since our founding and has been a cornerstone of how we act through both the successes and the challenges of our journey. We want to operate humbly, at the opposite side of arrogance. Our successes of the past do not guarantee success in the future. Similarly, the only way to not duplicate mistakes is to learn from them – we must accept where we could have done better. Being humble means you are willing to walk softly and listen carefully.

We must be humble in our interaction with each other. This means being honest and transparent, taking responsibility and holding ourselves accountable for our actions.

Governance

Corporate Governance

The highest governance body in our company is our Board of Directors, which is structured as a one-tier board under Dutch law, and which interacts regularly with our functional and project leaders. We report on the structure of our one-tier board, including its committees, its members and their background, expertise, tenure, independence, nationality, cross-board memberships, in the 'Governance' section on our website (Governance | Argenx).

Our risk and control systems as well as the risks we have identified as material to our business, are reported in detail in our 2021 annual report and on our website (Risk & Control Systems | Argenx).

We are subject to the Dutch Corporate Governance Code, which we are required to follow and to the extent we deviate from the best practice principles set out therein, we must report on this. For the year ended December 31, 2021 we complied with all best practice principles set out in the aforementioned governance code, with the exception of certain best practice principles relating to our remuneration practices. Each of these deviations and the reason thereof is explained in detail in the corporate governance statement included in our annual report. Each of these deviations is in line with our Remuneration Policy, which was revised in 2021 (Remuneration Policy | Argenx), and which carries broad investor support evidenced by the (76.58%) majority vote in favor at our May 11, 2021 Annual General Meeting.

Code of Business Conduct and Ethics

At argenx, we are on a journey together to achieve the unthinkable. We are all working hard to build an integrated, immunology company and reach patients. As we continue to scale up the business to achieve this vision, it is critical that we do so with integrity and passion. When each of us acts with honesty and integrity, we gain the trust of our colleagues, patients and communities.

Our Code of Business Conduct and Ethics reflects our core values: a way of working that celebrates innovation, co-creation, excellence, humility, and empowerment. Our Code translates the core values into a set of clear standards to help guide our conduct as we navigate the complexities of the highly regulated and competitive global marketplace in which we operate as we work to become an independent, fully integrated, and global immunology company.

Our commitment to the Code is an enabler to our core business of innovation and our culture of collaboration. As co-owners of the company, we are all dedicated to and responsible for its success. Each of us contribute to our reputation by living our core values every day and making the best choices for argenx and the many people we serve. All Argonauts are trained annually on our Code of Conduct and Business Ethics, and accepting, and committing to, the contents thereof is expected of all newcomers to argenx.

At argenx, we promote our products ethically and honestly, and only for the uses for which they have been approved. We believe that healthcare professionals and patients have the right to decide the most appropriate treatment options available based on truthful, accurate, and balanced product information that is supported by scientific evidence and is consistent with approved product labeling. We only use promotional material and other product information that have been approved through our internal review process. When acting in a promotional capacity, colleagues and agents of argenx are required to always give a balanced presentation of our products, including relevant safety information.

The Code of Business Conduct and Ethics covers:

- Respect for human rights (Pages 25-30)
- Anti-corruption and bribery matters (Page 36-37)

The full text of our Code of Business Conduct and Ethics can be found on our website

Animal Welfare

Given the present state of scientific knowledge, it is in many cases not possible to examine the complex interactions in a living organism solely by the use of modeling or performing experiments in cell cultures and tissue samples. Consequently, research using living animals remains essential in the discovery, development and production of new medicines, and regulatory authorities worldwide commonly require that new products have been evaluated in both animals and humans to ensure the quality, efficacy and safety of these products before granting approval.

In 2021, we incorporated a formal animal welfare policy. Even though we do not have our own animal research facilities, we do collaborate with third parties who engage in research activities involving live animals. To raise awareness of, and ensure compliance with, currently applicable laws, regulations and standards, we trained all employees who are involved in experiments with live animals on our animal welfare policy.

Metrics Reference Table

Topic	Category	Code	Unit of measure	Disclosure / reference
Safety of Clinical Trial Participants				
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Discussion & Analysis	HC-BP-210a.1	n/a	We ensured the continuous monitoring of the safety profile of our investigational product and ensured compliant adverse event reporting to health authorities worldwide. We also ensured supply to patients on clinical trials and have had no supply disruption.
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	Quantitative	HC-BP-210a.2	Number	Zero
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Quantitative	HCP-BP-210a.3	Reporting currency	argenx did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described.
Access to Medicines				
Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index	Discussion & Analysis	HC-BP-240a.1	n/a	N/A
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Discussion & Analysis	HC-BP-240a.2	n/a	Zero
Affordability and Pricing				
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Quantitative	HC-BP-240b.1	Number	Zero
Percentage change in:(1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Quantitative	HC-BP-240b.2	Percentage (%)	N/A – Our first medicine was approved on December 17, 2021
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Quantitative	HC-BP-240b.3	Percentage (%)	N/A – Our first medicine was approved on December 17, 2021

Metrics Reference Table

Drug Safety				
List of products listed in the Food and Drug Administration's (FDA) Med Watch Safety Alerts for Human Medical Products database	Discussion & Analysis	HC-BP-250a.1	n/a	There were no listings relevant to argenx's products on the FDA's MedWatch Safety Alerts for Human Medical Products database in 2021.
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Quantitative	HC-BP-250a.2	Number	Zero. All information related to adverse events, including any reported fatalities, associated with argenx products is available via the FDA Adverse Event Reporting System (AERS) database.
Number of recalls issued, total units recalled	Quantitative	HC-BP-250a.3	Number	Zero
Total amount of product accepted for take-back, reuse, or disposal	Quantitative	HC-BP-250a.4	Metric tons(t)	Zero
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Quantitative	HC-BP-250a.5	Number	Zero
Counterfeit Drugs				
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Discussion & Analysis	HC-BP-260a.1	n/a	To the extent this is required by national legislation (e.g. DSCSA in US and FMD in EU), all commercial argenx products are serialized at unit, case and pallet (aggregated level). On each sellable unit a unique random serial number is printed, as well as a product code, lot number and expiry date, both in human readable format and encoded in a 2D data matrix barcode. A dedicated software database is used to generate and maintain the status of the serial numbers and interface with the relevant partners in the supply chain. All products are tamper evident sealed during manufacture and also shipper systems and trucks are tagged with numbered seals in transit to prevent product tampering. During batch manufacturing (outsourced to CMOs), all processing steps are documented to have a full processing history and lot genealogy of consumed raw materials, which is also maintained in the entity's quality system. An ERP system is used to provide full lot genealogy and traceability of intermediates and finished products owned by the entity (argenx), located at its CMOs, third party warehouses and 3PL distributors, or in transit. For downstream distribution, the entity can rely on the distributors and wholesalers systems to trace product to the end customer, at lot level.

Metrics Reference Table

Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Discussion & Analysis	HC-BP-260a.2	n/a	argenx has a procedure in place to ensure that all suspicions of falsified or counterfeit medicine are reported in a consistent manner. When a case is reported, the impacted batches will be separated and quarantined, an investigation will be performed and the impacted stakeholders in the supply chain will be informed, as well as the relevant competent authorities in case of confirmed counterfeit product. Market actions will be taken in consultation with the competent authority.
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Quantitative	HC-BP-260a.3	Number	Zero
Ethical Marketing				
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Quantitative	HC-BP-270a.1	Reporting currency	Zero - argenx did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described. argenx discloses all material legal and regulatory proceedings in its Annual Report.
Description of code of ethics governing promotion of off-label use of products	Discussion & Analysis	HC-BP-270a.2	n/a	We comply with the Pharmaceutical Research and Manufacturers of America's (PhRMA) Code on Interactions with Healthcare Professionals. See our Code of Business Conduct and Ethics section on Ethical Promotion.
Employee Recruitment, Development& Retention				
Discussion of talent recruitment and retention efforts for scientists and research and development personnel	Discussion & Analysis	HC-BP-330a.1	n/a	See page 19
(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid- level managers, (c) professionals, and (d) all others	Quantitative	HC-BP-330a.2	Rate	Voluntary Turnover Rate: 4.42% as of February 1, 2022. Involuntary Turnover Rate: 1.03% as of February 1, 2022.

Metrics Reference Table

Supply Chain Management				
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third- party audit programs for integrity of supply chain and ingredients	Quantitative	HC-BP-430a.1	Percentage (%)	argenx' does not own production facilities. argenx partners with Lonza for its global manufacturing capabilities. Lonza is in the membership list. argenx has selected other top-tier suppliers across many of its outsourced operations, whether in preclinical, clinical or manufacturing and distribution operations of which some are participating in RX-360.
Business Ethics				
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Quantitative	HC-BP-510a.1	Reporting currency	argenx did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described. argenx discloses all material legal and regulatory proceedings in its Annual Report.
Description of code of ethics governing interactions with healthcare professionals	Discussion & Analysis	HC-BP-510a.2	n/a	We promote our products ethically and honestly, and only for the uses for which they have been approved. For more information see pages 23-34 of our Code of Business Conduct available on our website.
Number of Patients Treated				
Number of patients treated	Quantitative	HC-BP-000.A	Number	1,331 patients have been treated by our pipeline candidates in a clinical trial setting as of December 31, 2021. Data on patients treated with commercially available treatments is not yet publicly available.
Number of drugs (1) in portfolio and (2) in research and development (Phase 1-3)	Quantitative	HC-BP-000.B	Number	The number of drugs actively on the market is 1. As of December 31, 2021, we had the following number of clinical programs across two assets, efgartigimod and ARGX-117: • Number in Phase 1: 0 • Number in Phase 2: 1 • Number in Phase 3: 6 We expect to initiate one Phase 1 and five Phase 2 proof-of-concept trials in 2022. For more information on our pipeline please visit our website.

Reporting Practices

Legal information

This ESG report is published by argenx SE, a Societas Europaea incorporated under the laws of the Netherlands, with its registered statutory seat in Breda, the Netherlands and its office address at Willemstraat 5, 4811 AH in Breda, the Netherlands. argenx SE has its ordinary shares listed on the Euronext Brussels exchange, and American Depository Receipts of ordinary shares in its capital are listed on the NASDAQ exchange. argenx SE holds 100% of the shares in argenx IIP BV and argenx BV, both limited liability companies incorporated under the laws of Belgium with their office address at Industriepark Zwijnaarde 7, 9052 Zwijnaarde (Ghent), Belgium. argenx BV holds 100% of the shares in argenx US Inc., argenx Canada Inc., argenx Germany GmbH, argenx France SAS, argenx Switzerland SA and argenx Japan KK.

The activities of each of the aforementioned entities of the argenx group are consolidated in this ESG report, and references to 'we', 'our', 'the company' or 'argenx' should be read as a reference to the argenx group, unless otherwise indicated.

References to VYVGART® should be read as references to VYVGART® and its generic name as approved in the jurisdictions where marketing approval has been obtained at the date of this report, meaning in the United States of America (efgartigimod alfa fcab) and Japan (efgartigimod alfa).

Reporting period, frequency and contact point

Our Board of Directors reviews and approves this ESG Report, after discussing it with our senior executives. This ESG report is up-to-date as per 31 December 2021, unless another date is specified for certain information, which may be the case if we have access to more recent information which we deem relevant to include. In case of any questions regarding the contents of this report, please contact our team via the contact information specified on our website Contact us | Argenx

No assurance on the contents of this report

Information made available in this report is reviewed carefully by us, including by our board of directors and our senior management team, to limit inaccuracies, misstatements or errors. Notwithstanding, in the event of any discrepancy between this ESG Report and our consolidated financial statements for the period ending 31 December, 2021, the information in our consolidated financial statements shall prevail. This ESG report has not been externally assured, nor has it been subject any audit to ensure compliance with generally accepted accounting principles.

Forward looking statements

The contents of this ESG Report may include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "hope," "estimates," "anticipates," "expects," "intends," "may," "will," "aspires", or "should" and include statements argenx makes concerning its global launch strategy; its expectation concerning treatment options, scale of potential patients and impact and effect on patients; estimates concerning the commercialization potential of VYVGART®; expected approval of VYVGART® by European Medicines Agency of MAA in the second half of 2022; and evaluation of efgartigimod in up to ten high-need conditions by end of 2022. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.